文献速递胸部肿瘤

NSCLC根治性治疗后随访监测对复发/再发检测、再治疗及生存影响的系统评价与荟萃分析

Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Thorac Oncol · 2021-02-12

该系统评价与荟萃分析纳入前瞻性研究,评估NSCLC根治性治疗后随访对复发或第二原发肺癌(SPLC)检测、根治性再治疗及生存的影响。结果显示复发或SPLC发生率为17.8%至71%,计划影像发现60%至100%的复发,但CT或PET-CT随访未显著优于标准随访;检测到复发/SPLC显著增加根治性再治疗机会(OR=4.31),再治疗延长生存。

要点

  • 复发或SPLC发生率为17.8%至71%,计划影像可发现60%至100%的复发。
  • CT或PET-CT随访相比标准随访未显著提高复发检测优势。
  • 检测到复发/SPLC显著增加根治性再治疗机会并延长生存。

核心结论

  • 早期检测复发或SPLC可能增加根治性再治疗的可能性并延长生存。
  • 需要前瞻性随机对照研究确认现有随访模式的有效性。

研究设计与样本

  • 系统评价与荟萃分析,纳入关于NSCLC根治性治疗后随访的前瞻性研究。

主要发现

  • 复发或SPLC发生率为17.8%至71%。
  • 计划影像检测到60%至100%的复发。
  • CT随访相比标准随访检测复发的OR=2.31(95%CI 0.27-19.49,p=0.44),无统计学优势。
  • PET-CT随访相比标准随访检测复发的OR=1.431(95%CI 0.92-2.22,p=0.12),无统计学优势。
  • 检测到复发/SPLC显著增加根治性再治疗的OR=4.31(95%CI 2.10-8.84,p<0.0001)。

关键数值与推荐

  • 复发或SPLC发生率范围17.8%至71%。
  • 计划影像检测复发比例范围60%至100%。
  • CT随访对比标准随访OR=2.31(95%CI 0.27-19.49,p=0.44)。
  • PET-CT随访对比标准随访OR=1.431(95%CI 0.92-2.22,p=0.12)。
  • 检测复发/SPLC对根治性再治疗OR=4.31(95%CI 2.10-8.84,p<0.0001)。

临床怎么用

  • 随访中检测到复发或SPLC应积极评估根治性再治疗的可能性。
  • 现有证据不支持某种影像随访模式显著优于标准随访,需个体化选择。

局限性

  • 纳入研究为前瞻性研究,缺乏随机对照设计。
  • CT和PET-CT随访对比标准随访的检测优势未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with NSCLC may be treated with curative intent, yet they remain at high risk of both disease recurrence and second primary lung cancer (SPLC) and increased risk of early death. Guidelines provide recommendations for follow-up, but there is little consensus, and review of available evidence is necessary. The use of a systematic follow-up strategy for the detection of disease recurrence or SPLC after curative-intent treatment of NSCLC may increase the proportion of patients available for retreatment and increase the survival of patients with surveillance detection. METHODS: We performed a systematic review and meta-analysis of prospective studies on follow-up of NSCLC after curative-intent treatment to answer the following three questions: What is the effect of follow-up on detection of recurrence or SPLC? What is the effect of surveillance detection on curative-intent retreatment? What is the survival impact? RESULTS: Recurrence or SPLC was observed in 17.8% to 71% of patients. Scheduled imaging-detected recurrence in 60% to 100% of cases, yet neither computed tomography-based (OR = 2.31, 95% confidence interval [CI]: 0.27-19.49, p = 0.44) nor positron emission tomography-computed tomography-based follow-up (OR = 1.431, 95% CI: 0.92-2.22, p = 0.12) was statistically superior to standard follow-up strategies. Detection of disease recurrence/SPLC significantly increased the odds of curative-intent retreatment (OR = 4.31; 95% CI: 2.10-8.84, p < 0.0001). Curative-intent retreatment prolonged survival in reported studies. CONCLUSIONS: The early detection of disease recurrence/SPLC may increase the likelihood of curative-intent retreatment and prolong survival. There is a clear need for prospective randomized controlled studies of follow-up to confirm effectiveness of available follow-up modalities.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Stirling RG, Chau C, Shareh A, et al. Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2021. PMID: 33588110. doi:10.1016/j.jtho.2021.01.1622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。